Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) with fatigued chronic myelogenous leukemia (CML) patients on tyrosine kinase inhibitors (TKIs) for feasibility, acceptability and potential efficacy relative to usual care only in a small-scale randomized controlled trial.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02592447
Study type Interventional
Source H. Lee Moffitt Cancer Center and Research Institute
Contact
Status Completed
Phase N/A
Start date September 29, 2015
Completion date September 2, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Terminated NCT01397734 - Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Phase 1
Withdrawn NCT01011998 - A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) Phase 2
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00378534 - Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants Phase 2
Completed NCT00098033 - Investigation of Clofarabine in Acute Leukemias Phase 2
Terminated NCT00852709 - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Phase 1
Completed NCT02581007 - Reduced Intensity Conditioning Transplant Using Haploidentical Donors Phase 2
Terminated NCT03547154 - Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) Phase 2/Phase 3
Terminated NCT02709083 - Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia Phase 2
Terminated NCT02145039 - Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases N/A
Terminated NCT02146846 - Population Pharmacokinetics of Imatinib in CML Patients in Iran N/A
Active, not recruiting NCT01036009 - A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies Phase 2
Completed NCT00990587 - Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy Phase 1
Terminated NCT00500006 - A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) Phase 1
Terminated NCT00594308 - In-Vivo Activated T-Cell Depletion to Prevent GVHD N/A
Completed NCT00493181 - Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients Phase 2
Completed NCT00081926 - Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Phase 4